Marker Therapeutics Inc (MRKR)

[poods]

In the presentation PH made the new claim that PC responses "correlated perfectly" with patients who demonstrated epitope spreading. Prior to this claim they had only shown epitope expansion had occurred in some responding patients but did not correlate responses with epitope expansion (i.e it might have otherwise occurred in all patients and had no impact on tumor response). If what he claimed is true, this strongly suggests cause and effect and, thus, activity of multi-TAA in PC in the context of chemotherapy.
Furthermore, he claimed 9/15 CRs in the lymphoma group with no relapses. That again, if true, is amazing, especially for a non toxic treatment. In the presentation on the website I did not see this high # of CRs, so either PH is wrong or more CRs have occurred and this is new. Please correct me if I'm wrong here.